Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors
CA Milbury, J Creeden, WK Yip, DL Smith, V Pattani… - PLoS …, 2022 - journals.plos.org
FoundationOne® CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-
approved companion diagnostic test to identify patients who may benefit from treatment in …
approved companion diagnostic test to identify patients who may benefit from treatment in …
BRCA genetic testing and counseling in breast cancer: how do we meet our patients' needs?
P Dubsky, C Jackisch, SA Im, KK Hunt, CF Li… - NPJ Breast …, 2024 - nature.com
BRCA1 and BRCA2 are tumor suppressor genes that have been linked to inherited
susceptibility of breast cancer. Germline BRCA1/2 pathogenic or likely pathogenic variants …
susceptibility of breast cancer. Germline BRCA1/2 pathogenic or likely pathogenic variants …
Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted …
The Oncology Grand Rounds series is designed to place original reports published in the
Journal into clinical context. A case presentation is followed by a description of diagnostic …
Journal into clinical context. A case presentation is followed by a description of diagnostic …
[HTML][HTML] LuciA-15–a real-world prospective study of PARP inhibitors for the treatment of patients with HER-2 negative metastatic breast cancer with germline and/or …
FE Petracci, C Villarreal-Garza, F Argañaraz… - …, 2023 - ncbi.nlm.nih.gov
Background Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) improve
progression free survival among patients with HER2 negative (HER2-ve) advanced breast …
progression free survival among patients with HER2 negative (HER2-ve) advanced breast …
[HTML][HTML] Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised targeted therapies for solid malignancies …
JWG Derksen, D Martins-Branco, A Valachis… - ESMO Real World Data …, 2024 - Elsevier
Background The role of real-world evidence (RWE) for clinical efficacy regulatory evaluation
remains unclear. We aimed to assess and describe the reported use of RWE for clinical …
remains unclear. We aimed to assess and describe the reported use of RWE for clinical …
Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis
Purpose Cancers deficient in homologous recombination DNA repair, such as those with
BRCA1 or BRCA2 (BRCA1/2) mutations rely on a pathway mediated by the enzyme poly …
BRCA1 or BRCA2 (BRCA1/2) mutations rely on a pathway mediated by the enzyme poly …